Suppression of tumor recurrence and metastasis by a combination of the PHSCN sequence and the antiangiogenic compound tetrathiomolybdate in prostate carcinoma

Kenneth L. Van Golen, Liwei Bao, George J. Brewer, Kenneth Pienta, Jeffrey M. Kamradt, Donna L. Livant, Sofia D. Merajver

Research output: Contribution to journalArticle

Abstract

Plasma fibronectin-mediated invasion of human DU145 prostate cancer cell line was efficaciously inhibited in a rat tumor model by treatment with Ac-PHSCN-NH2 peptide. Invasion of DU145 cells was stimulated by the PHSRN sequence of plasma fibronectin. However, PHSCN acts as a competitive inhibitor of PHSRN-mediated invasion. In the current study, we determined whether PHSCN could inhibit the recurrence and metastasis of DU145 tumors after excision of the primary tumor in an athymic nude mouse model. We demonstrated that mice treated thrice weekly with intravenous Ac-PHSCN-NH2 peptide survived tumor-free for more than 30 weeks post-primary tumor excision, whereas their untreated counterparts succumbed to recurrence and/or metastatic disease in significantly less time. Because of the universal requirement for angiogenesis in solid tumor growth, we tested the efficacy of copper deficiency induced by tetrathiomolybdate (TM) to retard tumor growth in the Dunning prostate cancer model. Significant reduction in size of the primary tumor was observed in mice rendered copper deficient. We sought to reduce tumor growth at the primary and metastatic sites by combining the anti-invasion Ac-PHSCN-NH2 peptide with TM. Improved survival, fewer metastatic lesions, and excellent tolerability were observed with the combination therapy.

Original languageEnglish (US)
Pages (from-to)373-379
Number of pages7
JournalNeoplasia
Volume4
Issue number5
DOIs
StatePublished - Sep 2002
Externally publishedYes

Fingerprint

Prostate
Neoplasm Metastasis
Carcinoma
Recurrence
Neoplasms
Fibronectins
Nude Mice
Peptides
Copper
Prostatic Neoplasms
Growth
tetrathiomolybdate
Binding Sites
Cell Line
Survival
acetyl-prolyl-histidyl-seryl-cysteinyl-asparaginamide

Keywords

  • Metastasis
  • PHSCN
  • Prostate carcinoma
  • Tetrathiomolybdate
  • Tumor recurrence

ASJC Scopus subject areas

  • Cancer Research

Cite this

Suppression of tumor recurrence and metastasis by a combination of the PHSCN sequence and the antiangiogenic compound tetrathiomolybdate in prostate carcinoma. / Van Golen, Kenneth L.; Bao, Liwei; Brewer, George J.; Pienta, Kenneth; Kamradt, Jeffrey M.; Livant, Donna L.; Merajver, Sofia D.

In: Neoplasia, Vol. 4, No. 5, 09.2002, p. 373-379.

Research output: Contribution to journalArticle

Van Golen, Kenneth L. ; Bao, Liwei ; Brewer, George J. ; Pienta, Kenneth ; Kamradt, Jeffrey M. ; Livant, Donna L. ; Merajver, Sofia D. / Suppression of tumor recurrence and metastasis by a combination of the PHSCN sequence and the antiangiogenic compound tetrathiomolybdate in prostate carcinoma. In: Neoplasia. 2002 ; Vol. 4, No. 5. pp. 373-379.
@article{eefe3c98987d40fba2a580184139a3bc,
title = "Suppression of tumor recurrence and metastasis by a combination of the PHSCN sequence and the antiangiogenic compound tetrathiomolybdate in prostate carcinoma",
abstract = "Plasma fibronectin-mediated invasion of human DU145 prostate cancer cell line was efficaciously inhibited in a rat tumor model by treatment with Ac-PHSCN-NH2 peptide. Invasion of DU145 cells was stimulated by the PHSRN sequence of plasma fibronectin. However, PHSCN acts as a competitive inhibitor of PHSRN-mediated invasion. In the current study, we determined whether PHSCN could inhibit the recurrence and metastasis of DU145 tumors after excision of the primary tumor in an athymic nude mouse model. We demonstrated that mice treated thrice weekly with intravenous Ac-PHSCN-NH2 peptide survived tumor-free for more than 30 weeks post-primary tumor excision, whereas their untreated counterparts succumbed to recurrence and/or metastatic disease in significantly less time. Because of the universal requirement for angiogenesis in solid tumor growth, we tested the efficacy of copper deficiency induced by tetrathiomolybdate (TM) to retard tumor growth in the Dunning prostate cancer model. Significant reduction in size of the primary tumor was observed in mice rendered copper deficient. We sought to reduce tumor growth at the primary and metastatic sites by combining the anti-invasion Ac-PHSCN-NH2 peptide with TM. Improved survival, fewer metastatic lesions, and excellent tolerability were observed with the combination therapy.",
keywords = "Metastasis, PHSCN, Prostate carcinoma, Tetrathiomolybdate, Tumor recurrence",
author = "{Van Golen}, {Kenneth L.} and Liwei Bao and Brewer, {George J.} and Kenneth Pienta and Kamradt, {Jeffrey M.} and Livant, {Donna L.} and Merajver, {Sofia D.}",
year = "2002",
month = "9",
doi = "10.1038/sj.neo.7900258",
language = "English (US)",
volume = "4",
pages = "373--379",
journal = "Neoplasia",
issn = "1522-8002",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Suppression of tumor recurrence and metastasis by a combination of the PHSCN sequence and the antiangiogenic compound tetrathiomolybdate in prostate carcinoma

AU - Van Golen, Kenneth L.

AU - Bao, Liwei

AU - Brewer, George J.

AU - Pienta, Kenneth

AU - Kamradt, Jeffrey M.

AU - Livant, Donna L.

AU - Merajver, Sofia D.

PY - 2002/9

Y1 - 2002/9

N2 - Plasma fibronectin-mediated invasion of human DU145 prostate cancer cell line was efficaciously inhibited in a rat tumor model by treatment with Ac-PHSCN-NH2 peptide. Invasion of DU145 cells was stimulated by the PHSRN sequence of plasma fibronectin. However, PHSCN acts as a competitive inhibitor of PHSRN-mediated invasion. In the current study, we determined whether PHSCN could inhibit the recurrence and metastasis of DU145 tumors after excision of the primary tumor in an athymic nude mouse model. We demonstrated that mice treated thrice weekly with intravenous Ac-PHSCN-NH2 peptide survived tumor-free for more than 30 weeks post-primary tumor excision, whereas their untreated counterparts succumbed to recurrence and/or metastatic disease in significantly less time. Because of the universal requirement for angiogenesis in solid tumor growth, we tested the efficacy of copper deficiency induced by tetrathiomolybdate (TM) to retard tumor growth in the Dunning prostate cancer model. Significant reduction in size of the primary tumor was observed in mice rendered copper deficient. We sought to reduce tumor growth at the primary and metastatic sites by combining the anti-invasion Ac-PHSCN-NH2 peptide with TM. Improved survival, fewer metastatic lesions, and excellent tolerability were observed with the combination therapy.

AB - Plasma fibronectin-mediated invasion of human DU145 prostate cancer cell line was efficaciously inhibited in a rat tumor model by treatment with Ac-PHSCN-NH2 peptide. Invasion of DU145 cells was stimulated by the PHSRN sequence of plasma fibronectin. However, PHSCN acts as a competitive inhibitor of PHSRN-mediated invasion. In the current study, we determined whether PHSCN could inhibit the recurrence and metastasis of DU145 tumors after excision of the primary tumor in an athymic nude mouse model. We demonstrated that mice treated thrice weekly with intravenous Ac-PHSCN-NH2 peptide survived tumor-free for more than 30 weeks post-primary tumor excision, whereas their untreated counterparts succumbed to recurrence and/or metastatic disease in significantly less time. Because of the universal requirement for angiogenesis in solid tumor growth, we tested the efficacy of copper deficiency induced by tetrathiomolybdate (TM) to retard tumor growth in the Dunning prostate cancer model. Significant reduction in size of the primary tumor was observed in mice rendered copper deficient. We sought to reduce tumor growth at the primary and metastatic sites by combining the anti-invasion Ac-PHSCN-NH2 peptide with TM. Improved survival, fewer metastatic lesions, and excellent tolerability were observed with the combination therapy.

KW - Metastasis

KW - PHSCN

KW - Prostate carcinoma

KW - Tetrathiomolybdate

KW - Tumor recurrence

UR - http://www.scopus.com/inward/record.url?scp=0036708501&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036708501&partnerID=8YFLogxK

U2 - 10.1038/sj.neo.7900258

DO - 10.1038/sj.neo.7900258

M3 - Article

VL - 4

SP - 373

EP - 379

JO - Neoplasia

JF - Neoplasia

SN - 1522-8002

IS - 5

ER -